Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

iSpecimen (ISPC) Research & Development (2020 - 2025)

iSpecimen has reported Research & Development over the past 6 years, most recently at $527033.0 for Q4 2025.

  • For Q4 2025, Research & Development fell 44.62% year-over-year to $527033.0; the TTM value through Dec 2025 reached $2.2 million, down 38.82%, while the annual FY2025 figure was $2.2 million, 38.82% down from the prior year.
  • Research & Development for Q4 2025 was $527033.0 at iSpecimen, down from $551104.0 in the prior quarter.
  • Over five years, Research & Development peaked at $967831.0 in Q4 2023 and troughed at $361799.0 in Q2 2021.
  • A 5-year average of $687559.6 and a median of $688030.0 in 2022 define the central range for Research & Development.
  • Biggest five-year swings in Research & Development: surged 75.69% in 2022 and later plummeted 44.62% in 2025.
  • Year by year, Research & Development stood at $522551.0 in 2021, then skyrocketed by 41.69% to $740410.0 in 2022, then surged by 30.72% to $967831.0 in 2023, then decreased by 1.67% to $951667.0 in 2024, then plummeted by 44.62% to $527033.0 in 2025.
  • Business Quant data shows Research & Development for ISPC at $527033.0 in Q4 2025, $551104.0 in Q3 2025, and $536311.0 in Q2 2025.